This case-control study uses data from the Centers for Disease Control and Prevention Increasing Community Access to Testing platform to estimate the association between receipt of 3 doses of Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccine, compared with 2 doses or unvaccinated, and symptomatic SARS-CoV-2 infection, stratified by Omicron and Delta variant.
Source: JAMA Online First